Cytek Financial Statements From 2010 to 2025

CTKB Stock  USD 5.13  0.09  1.72%   
Cytek Biosciences financial statements provide useful quarterly and yearly information to potential Cytek Biosciences investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Cytek Biosciences financial statements helps investors assess Cytek Biosciences' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Cytek Biosciences' valuation are summarized below:
Gross Profit
110.5 M
Profit Margin
(0.05)
Market Capitalization
660.8 M
Enterprise Value Revenue
1.9821
Revenue
201.2 M
We have found one hundred twenty available fundamental signals for Cytek Biosciences, which can be analyzed and compared to other ratios and to its rivals. All investors should make sure to validate all of Cytek Biosciences prevailing market performance against the performance between 2010 and 2025 to make sure the company can sustain itself down the road. The current year's Market Cap is expected to grow to about 2.2 B. The current year's Enterprise Value is expected to grow to about 1.9 B

Cytek Biosciences Total Revenue

139.86 Million

Check Cytek Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cytek Biosciences' main balance sheet or income statement drivers, such as Net Interest Income of 6.3 M, Interest Income of 9.2 M or Depreciation And Amortization of 11.1 M, as well as many indicators such as Price To Sales Ratio of 6.98, Dividend Yield of 0.0 or PTB Ratio of 2.97. Cytek financial statements analysis is a perfect complement when working with Cytek Biosciences Valuation or Volatility modules.
  
Check out the analysis of Cytek Biosciences Correlation against competitors.
For information on how to trade Cytek Stock refer to our How to Trade Cytek Stock guide.

Cytek Biosciences Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets389 M568.6 M209.9 M
Slightly volatile
Other Current Liabilities21 M30.1 M13.7 M
Slightly volatile
Total Current Liabilities40.7 M64.7 M30 M
Slightly volatile
Other Liabilities23.8 M34.9 M20.2 M
Slightly volatile
Property Plant And Equipment Net35.3 M33.6 MM
Slightly volatile
Current Deferred Revenue27.4 M26.1 M8.5 M
Slightly volatile
Accounts Payable3.6 M3.5 M2.8 M
Slightly volatile
Cash225.3 M192.4 M107 M
Slightly volatile
Non Current Assets Total123.6 M117.8 M29.9 M
Slightly volatile
Other Assets1.091.153.1 M
Slightly volatile
Cash And Short Term Investments256 M301.8 M124.5 M
Slightly volatile
Net Receivables37.5 M64.5 M27 M
Slightly volatile
Good Will19.5 M18.6 MM
Slightly volatile
Common Stock Total Equity83.9 K155.2 K54.3 K
Slightly volatile
Common Stock Shares Outstanding148.2 M155.6 M135.9 M
Slightly volatile
Liabilities And Stockholders Equity389 M568.6 M209.9 M
Slightly volatile
Non Current Liabilities Total66.4 M40.7 M83.8 M
Slightly volatile
Inventory40.2 M70 M28.7 M
Slightly volatile
Other Current Assets8.4 M14.6 MM
Slightly volatile
Total Liabilities96 M91.3 M112.3 M
Pretty Stable
Property Plant And Equipment Gross42.5 M40.5 M10.4 M
Slightly volatile
Total Current Assets342 M450.9 M184.8 M
Slightly volatile
Capital Stock95.9 K150.7 K54.5 K
Slightly volatile
Non Current Liabilities Other19.7 M21.7 M16.4 M
Slightly volatile
Net Working Capital301.3 M386.2 M154.8 M
Slightly volatile
Short Term Debt3.3 M3.5 MM
Pretty Stable
Intangible Assets27.9 M26.5 M5.6 M
Slightly volatile
Common Stock95.9 K150.7 K54.5 K
Slightly volatile
Property Plant Equipment16.5 M15.7 M4.9 M
Slightly volatile
Short and Long Term Debt Total12.8 M16.3 M6.9 M
Slightly volatile
Short and Long Term Debt483.1 K508.5 K2.1 M
Slightly volatile
Capital Surpluse476.6 M509.3 M434.7 M
Slightly volatile
Deferred Long Term Liabilities12.6 M15.1 M10.7 M
Slightly volatile
Long Term Debt1.6 M1.5 M2.1 M
Slightly volatile
Long Term Debt Total1.8 MM2.2 M
Slightly volatile

Cytek Biosciences Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Interest Income9.2 M8.7 M2.3 M
Slightly volatile
Depreciation And Amortization11.1 M10.6 M2.6 M
Slightly volatile
Interest Expense1.5 M2.4 M661.7 K
Slightly volatile
Selling General Administrative25.1 M48.8 M15.5 M
Slightly volatile
Selling And Marketing Expenses29.1 M56.5 M19.4 M
Slightly volatile
Total Revenue139.9 M222 M94.9 M
Slightly volatile
Gross Profit81.4 M125.8 M52.2 M
Slightly volatile
Other Operating Expenses140.8 M254 M95.7 M
Slightly volatile
Research Development27.7 M50.8 M17.8 M
Slightly volatile
Cost Of Revenue58.5 M96.1 M42.7 M
Slightly volatile
Total Operating Expenses82.3 M157.9 M53 M
Slightly volatile
Reconciled Depreciation10.5 M10 M2.5 M
Slightly volatile
Non Operating Income Net Other6.8 M6.5 M1.6 M
Slightly volatile

Cytek Biosciences Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation26.6 M25.4 M6.3 M
Slightly volatile
Begin Period Cash Flow199.3 M344.4 M116 M
Slightly volatile
Other Cashflows From Financing Activities2.5 M2.6 M29 M
Pretty Stable
Depreciation11.1 M10.6 M2.6 M
Slightly volatile
Capital Expenditures4.7 M5.6 M2.5 M
Slightly volatile
End Period Cash Flow226.2 M192.8 M107.6 M
Slightly volatile
Change To Netincome21 M20 M6.3 M
Slightly volatile
Dividends Paid922.4 K1.7 M424.7 K
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio6.987.3531.5039
Slightly volatile
Days Sales Outstanding77.2695.51104
Slightly volatile
Stock Based Compensation To Revenue0.110.10.0331
Slightly volatile
Capex To Depreciation0.570.62.5628
Slightly volatile
EV To Sales6.126.4430.6249
Slightly volatile
Inventory Turnover1.661.581.567
Pretty Stable
Days Of Inventory On Hand195239233
Pretty Stable
Payables Turnover13.3124.8114.5993
Slightly volatile
Sales General And Administrative To Revenue0.130.20.1368
Slightly volatile
Research And Ddevelopement To Revenue0.150.210.1677
Slightly volatile
Capex To Revenue0.02440.02250.0219
Slightly volatile
Cash Per Share1.381.750.865
Slightly volatile
Days Payables Outstanding26.2115.2326.4979
Slightly volatile
Intangibles To Total Assets0.0750.07150.0246
Slightly volatile
Current Ratio6.526.285.1585
Slightly volatile
Receivables Turnover4.293.963.5682
Slightly volatile
Graham Number2.292.181.2275
Slightly volatile
Capex Per Share0.02570.03210.0178
Slightly volatile
Revenue Per Share0.761.280.6683
Slightly volatile
Interest Debt Per Share0.110.11980.0331
Slightly volatile
Debt To Assets0.02020.02570.0177
Slightly volatile
Operating Cycle272335337
Pretty Stable
Days Of Payables Outstanding26.2115.2326.4979
Slightly volatile
Long Term Debt To Capitalization0.00520.00480.0052
Slightly volatile
Quick Ratio5.755.34.2558
Slightly volatile
Net Income Per E B T0.950.71.0552
Very volatile
Cash Ratio4.482.683.0041
Slightly volatile
Cash Conversion Cycle253323311
Very volatile
Days Of Inventory Outstanding195239233
Pretty Stable
Days Of Sales Outstanding77.2695.51104
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.09390.09890.8593
Slightly volatile
Fixed Asset Turnover7.217.5940.5395
Slightly volatile
Debt Ratio0.02020.02570.0177
Slightly volatile
Price Sales Ratio6.987.3531.5039
Slightly volatile
Asset Turnover0.50.450.6613
Slightly volatile
Gross Profit Margin0.460.510.5176
Slightly volatile

Cytek Biosciences Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap2.2 B1.4 B2.2 B
Slightly volatile
Enterprise Value1.9 B1.2 B2.1 B
Slightly volatile

Cytek Fundamental Market Drivers

Forward Price Earnings370.3704
Cash And Short Term Investments262.4 M

Cytek Upcoming Events

27th of February 2024
Upcoming Quarterly Report
View
14th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
27th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Cytek Biosciences Financial Statements

Cytek Biosciences stakeholders use historical fundamental indicators, such as Cytek Biosciences' revenue or net income, to determine how well the company is positioned to perform in the future. Although Cytek Biosciences investors may analyze each financial statement separately, they are all interrelated. For example, changes in Cytek Biosciences' assets and liabilities are reflected in the revenues and expenses on Cytek Biosciences' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Cytek Biosciences. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue26.1 M27.4 M
Total Revenue222 M139.9 M
Cost Of Revenue96.1 M58.5 M
Stock Based Compensation To Revenue 0.10  0.11 
Sales General And Administrative To Revenue 0.20  0.13 
Research And Ddevelopement To Revenue 0.21  0.15 
Capex To Revenue 0.02  0.02 
Revenue Per Share 1.28  0.76 
Ebit Per Revenue(0.17)(0.16)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Cytek Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Cytek Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cytek Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cytek Biosciences Stock:
Check out the analysis of Cytek Biosciences Correlation against competitors.
For information on how to trade Cytek Stock refer to our How to Trade Cytek Stock guide.
You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cytek Biosciences. If investors know Cytek will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cytek Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.658
Earnings Share
(0.08)
Revenue Per Share
1.527
Quarterly Revenue Growth
0.073
Return On Assets
(0.03)
The market value of Cytek Biosciences is measured differently than its book value, which is the value of Cytek that is recorded on the company's balance sheet. Investors also form their own opinion of Cytek Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Cytek Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cytek Biosciences' market value can be influenced by many factors that don't directly affect Cytek Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cytek Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cytek Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cytek Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.